AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Humana Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name “Dyadic Applied BioSolutions.â€� The filing clarifies that the legal corporate name remains “Dyadic International, Inc.,â€� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished—not filed—thereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato il modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, l'azienda inizierà a operare con il nome commerciale “Dyadic Applied BioSolutions.� Il documento specifica che la ragione sociale legale rimane “Dyadic International, Inc.,� il ticker DYAI non cambia e la società continuerà a essere quotata sul Nasdaq Stock Market. La comunicazione è fornita ai sensi della voce 7.01 (Regolamento FD) ed è fornita come informazione - non come deposito ufficiale - quindi non comporta responsabilità ai sensi della Sezione 18 né impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto comunica esclusivamente la futura denominazione DBA e allega il comunicato stampa correlato come Allegato 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) presentó un Formulario 8-K el 2 de julio de 2025 para informar una actualización de marca. En 30 días, la empresa comenzará a operar bajo el nombre comercial “Dyadic Applied BioSolutions.� El documento aclara que el nombre legal corporativo sigue siendo “Dyadic International, Inc.,� el símbolo DYAI no cambia y la empresa continuará cotizando en el Nasdaq Stock Market. La divulgación se realiza bajo el ítem 7.01 (Regulación FD) y se proporciona como información, no como un archivo oficial, por lo que no conlleva responsabilidad bajo la Sección 18 ni impacto directo en los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estratégicas; el informe únicamente comunica la próxima designación DBA y adjunta el comunicado de prensa relacionado como Anexo 99.1.

Dyadic International, Inc. (나스ë‹�: DYAI)ëŠ� 2025ë…� 7ì›� 2ì� 브랜ë“� ì—…ë°ì´íЏë¥� 공시하기 위해 Form 8-Kë¥� 제출했습니다. 30ì� í›� 회사ëŠ� “Dyadic Applied BioSolutions.â€�ë¼ëŠ” ìƒí˜¸ë¡� ì˜ì—…ì� 시작í•� 예정입니ë‹�. 제출 문서ì—는 ë²•ì  ë²•ì¸ëª…ì€ ì—¬ì „íž� “Dyadic International, Inc.â€ì´ë©�, DYAI 티커ëŠ� 변경ë˜ì§€ 않고 회사ëŠ� 나스ë‹� 주ì‹ì‹œìž¥ì—� ê³„ì† ìƒìž¥ë� 것임ì� 명확íž� 하고 있습니다. ì� 공시ëŠ� 항목 7.01(Regulation FD)ì—� ë”°ë¼ ì œê³µë˜ë©°, ê³µì‹ ì œì¶œì� 아닌 제공(furnished) 형태ë¡�, 섹션 18 ì±…ìž„ì� 없고 재무제표ì—� ì§ì ‘ì ì¸ ì˜í–¥ì� 없습니다. 재무 ë°ì´í„�, ìš´ì˜ ë³€ê²� ë˜ëŠ” ì „ëžµì � 거래ëŠ� í¬í•¨ë˜ì–´ 있지 않으ë©�, ì´ë²ˆ 보고서는 다가오는 DBA 명칭 ë³€ê²½ì„ ì•Œë¦¬ê³� ê´€ë � ë³´ë„ìžë£Œë¥� ë¶€ì†ì„œ 99.1ë¡� 첨부하는 ë‚´ìš©ë§� ë‹´ê³  있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a déposé un formulaire 8-K le 2 juillet 2025 pour annoncer une mise à jour de sa marque. Dans 30 jours, la société commencera à opérer sous le nom commercial « Dyadic Applied BioSolutions. » Le dépôt précise que le nom légal de la société reste « Dyadic International, Inc. », que le symbole DYAI ne change pas et que la société continuera à être cotée sur le Nasdaq Stock Market. La communication est effectuée en vertu de l'article 7.01 (Règlement FD) et est fournie � non déposée � ce qui exclut toute responsabilité en vertu de la Section 18 et n’a aucun impact direct sur les états financiers. Aucune donnée financière, révision opérationnelle ou transaction stratégique n’est incluse ; le rapport se limite à annoncer la future désignation DBA et fournit le communiqué de presse associé en Annexe 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Markenupdate bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Handelsnamen „Dyadic Applied BioSolutions.� tätig sein. Die Einreichung stellt klar, dass der rechtliche Firmenname weiterhin „Dyadic International, Inc.� lautet, das DYAI-Tickersymbol unverändert bleibt und das Unternehmen weiterhin an der Nasdaq-Börse gehandelt wird. Die Offenlegung erfolgt gemäß Punkt 7.01 (Regulation FD) und wird als Bereitstellung � nicht als Einreichung � vorgenommen, wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operative Änderungen oder strategische Transaktionen enthalten; der Bericht informiert ausschließlich über die bevorstehende DBA-Bezeichnung und enthält die zugehörige Pressemitteilung als Anlage 99.1.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Name-only rebranding; no change to DYAI’s financial outlook or Nasdaq listing—overall neutral.

Investors face no immediate economic consequences from the new DBA. The filing contains no revenue, cost, or guidance updates, and the legal entity, reporting obligations, and ticker symbol remain intact. As such, valuation models and risk profiles should remain unchanged. Branding exercises can signal strategic repositioning, but without supporting detail this event is non-material for near-term cash flows or capital structure.

TL;DR: Administrative disclosure compliant with Reg FD; governance impact minimal.

The company properly used Item 7.01 to furnish market-wide notice, limiting liability exposure. Because the legal name is preserved, charter documents and existing contracts require no amendments. The 30-day lead time affords counterparties notice, while retaining the DYAI symbol avoids market-confusion. Overall governance risk remains unchanged.

Dyadic International, Inc. (Nasdaq: DYAI) ha presentato il modulo 8-K il 2 luglio 2025 per comunicare un aggiornamento del marchio. Tra 30 giorni, l'azienda inizierà a operare con il nome commerciale “Dyadic Applied BioSolutions.� Il documento specifica che la ragione sociale legale rimane “Dyadic International, Inc.,� il ticker DYAI non cambia e la società continuerà a essere quotata sul Nasdaq Stock Market. La comunicazione è fornita ai sensi della voce 7.01 (Regolamento FD) ed è fornita come informazione - non come deposito ufficiale - quindi non comporta responsabilità ai sensi della Sezione 18 né impatti diretti sui bilanci. Non sono inclusi dati finanziari, modifiche operative o transazioni strategiche; il rapporto comunica esclusivamente la futura denominazione DBA e allega il comunicato stampa correlato come Allegato 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) presentó un Formulario 8-K el 2 de julio de 2025 para informar una actualización de marca. En 30 días, la empresa comenzará a operar bajo el nombre comercial “Dyadic Applied BioSolutions.� El documento aclara que el nombre legal corporativo sigue siendo “Dyadic International, Inc.,� el símbolo DYAI no cambia y la empresa continuará cotizando en el Nasdaq Stock Market. La divulgación se realiza bajo el ítem 7.01 (Regulación FD) y se proporciona como información, no como un archivo oficial, por lo que no conlleva responsabilidad bajo la Sección 18 ni impacto directo en los estados financieros. No se incluyen datos financieros, cambios operativos ni transacciones estratégicas; el informe únicamente comunica la próxima designación DBA y adjunta el comunicado de prensa relacionado como Anexo 99.1.

Dyadic International, Inc. (나스ë‹�: DYAI)ëŠ� 2025ë…� 7ì›� 2ì� 브랜ë“� ì—…ë°ì´íЏë¥� 공시하기 위해 Form 8-Kë¥� 제출했습니다. 30ì� í›� 회사ëŠ� “Dyadic Applied BioSolutions.â€�ë¼ëŠ” ìƒí˜¸ë¡� ì˜ì—…ì� 시작í•� 예정입니ë‹�. 제출 문서ì—는 ë²•ì  ë²•ì¸ëª…ì€ ì—¬ì „íž� “Dyadic International, Inc.â€ì´ë©�, DYAI 티커ëŠ� 변경ë˜ì§€ 않고 회사ëŠ� 나스ë‹� 주ì‹ì‹œìž¥ì—� ê³„ì† ìƒìž¥ë� 것임ì� 명확íž� 하고 있습니다. ì� 공시ëŠ� 항목 7.01(Regulation FD)ì—� ë”°ë¼ ì œê³µë˜ë©°, ê³µì‹ ì œì¶œì� 아닌 제공(furnished) 형태ë¡�, 섹션 18 ì±…ìž„ì� 없고 재무제표ì—� ì§ì ‘ì ì¸ ì˜í–¥ì� 없습니다. 재무 ë°ì´í„�, ìš´ì˜ ë³€ê²� ë˜ëŠ” ì „ëžµì � 거래ëŠ� í¬í•¨ë˜ì–´ 있지 않으ë©�, ì´ë²ˆ 보고서는 다가오는 DBA 명칭 ë³€ê²½ì„ ì•Œë¦¬ê³� ê´€ë � ë³´ë„ìžë£Œë¥� ë¶€ì†ì„œ 99.1ë¡� 첨부하는 ë‚´ìš©ë§� ë‹´ê³  있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a déposé un formulaire 8-K le 2 juillet 2025 pour annoncer une mise à jour de sa marque. Dans 30 jours, la société commencera à opérer sous le nom commercial « Dyadic Applied BioSolutions. » Le dépôt précise que le nom légal de la société reste « Dyadic International, Inc. », que le symbole DYAI ne change pas et que la société continuera à être cotée sur le Nasdaq Stock Market. La communication est effectuée en vertu de l'article 7.01 (Règlement FD) et est fournie � non déposée � ce qui exclut toute responsabilité en vertu de la Section 18 et n’a aucun impact direct sur les états financiers. Aucune donnée financière, révision opérationnelle ou transaction stratégique n’est incluse ; le rapport se limite à annoncer la future désignation DBA et fournit le communiqué de presse associé en Annexe 99.1.

Dyadic International, Inc. (Nasdaq: DYAI) reichte am 2. Juli 2025 ein Formular 8-K ein, um ein Markenupdate bekannt zu geben. In 30 Tagen wird das Unternehmen unter dem Handelsnamen „Dyadic Applied BioSolutions.� tätig sein. Die Einreichung stellt klar, dass der rechtliche Firmenname weiterhin „Dyadic International, Inc.� lautet, das DYAI-Tickersymbol unverändert bleibt und das Unternehmen weiterhin an der Nasdaq-Börse gehandelt wird. Die Offenlegung erfolgt gemäß Punkt 7.01 (Regulation FD) und wird als Bereitstellung � nicht als Einreichung � vorgenommen, wodurch keine Haftung nach Abschnitt 18 entsteht und keine direkten Auswirkungen auf die Finanzberichte vorliegen. Es sind keine Finanzdaten, operative Änderungen oder strategische Transaktionen enthalten; der Bericht informiert ausschließlich über die bevorstehende DBA-Bezeichnung und enthält die zugehörige Pressemitteilung als Anlage 99.1.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HILZINGER KURT J

(Last) (First) (Middle)
HUMANA INC.
500 W. MAIN STREET

(Street)
LOUISVILLE KY 40202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HUMANA INC [ HUM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Humana Common 19,448 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(1) (1) (1) (1) Humana Common 24,034 24,034(1) D
Restricted Stock Units(2) (2) (2) (2) Humana Common 2,753 2,753 D
Restricted Stock Units(3) (3) 06/30/2025 A 399 (3) (3) Humana Common 399 $242.815 15,044 D
Explanation of Responses:
1. Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.
2. Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
3. Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.
Kurt J. Hilzinger 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why is Dyadic International (DYAI) issuing an 8-K on July 2, 2025?

To announce that it will begin doing business as Dyadic Applied BioSolutions effective in 30 days.

When does the new DBA "Dyadic Applied BioSolutions" become effective?

The change takes effect 30 days after the July 2, 2025 press release.

Will Dyadic’s legal corporate name or Nasdaq ticker change?

No. The legal name remains Dyadic International, Inc. and the ticker stays DYAI.

Does the rebranding affect Dyadic’s financial statements or guidance?

The 8-K includes no financial data and states the information is furnished, not filed; financials are unaffected.

Where can investors read the full press release about the name change?

It is filed as Exhibit 99.1 to the Form 8-K dated July 2, 2025.

Which SEC item does Dyadic use to disclose the DBA change?

Item 7.01 (Regulation FD Disclosure).
Humana

NYSE:HUM

HUM Rankings

HUM Latest News

HUM Latest SEC Filings

HUM Stock Data

28.79B
120.40M
0.2%
97.78%
3.03%
Healthcare Plans
Hospital & Medical Service Plans
United States
LOUISVILLE